BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260624T130000
DTEND;TZID=America/New_York:20260624T143000
DTSTAMP:20260617T164249
CREATED:20260616T183403Z
LAST-MODIFIED:20260617T140909Z
UID:3080-1782306000-1782311400@lifescievents.com
SUMMARY:Elicio Therapeutics Virtual KOL Event To Discuss Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
DESCRIPTION:Please join the Elicio Therapeutics management team for a virtual key opinion leader (KOL) event to discuss complete radiographic and complete metabolic responses in patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent therapy. \nThe event will feature insights from leading experts: \n\nPeter Hosein\, M.D. – Professor of Clinical Medicine\, Sylvester Comprehensive Cancer Center\, University of Miami\nZev Wainberg\, M.D. – Professor of Medicine\, UCLA\, Co-Director of the UCLA GI Oncology Program\n\nChristopher Haqq\, M.D. Ph.D. Chief Medical Officer\, Elicio Therapeutics will also review Elicio’s plans to evaluate ELI-002 7P in combination with checkpoint inhibition and standard therapy in metastatic pancreatic cancer in a Phase 1 study\, which\, if successful\, could allow for a more rapid development pathway for ELI-002 7P. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/ekl48tp1/.
URL:https://lifescievents.com/event/ekl48tp1/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/06/Elicio-Banner.png
END:VEVENT
END:VCALENDAR